secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001104659-25-046155
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Elutia Issues Shares to Ligand, Amends SWK Loan, and Reports 84% Sequential EluPro Growth
--------------------------------------------------------------------------------

- Issued 1,105,528 shares to Ligand Pharmaceuticals to satisfy $2.2 million in royalty obligations.
- Amended SWK credit facility allowing full PIK interest in May 2025 and potential $5.0 million additional term loan.
- Reported Q1 2025 net sales of $6.0 million; BioEnvelope sales up 31% year-over-year to $3.1 million driven by 84% sequential EluPro growth.
- Entered partnership with Boston Scientific expected to accelerate EluPro adoption starting Q2 2025.
- Cash balance of $17.4 million as of March 31, 2025; raised $15.0 million in gross proceeds from direct offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465925046155/0001104659-25-046155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465925046155/tm2514493d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-046155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer